Pharmaceutical firm Bristol-Myers Squibb has announced a voluntary recall of one lot of Eliquis (apixaban) 5mg tablets following a consumer complaint that their bottle contained 2.5mg tablets. The affected lot is a 60-count bottle containing 5mg tablets of the medication and it was distributed nationwide. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA) and wholesalers and pharmacies have been notified of the issues and arrangements made for the return and replacement of recalled products.
Eliquis (apixaban) is an anticoagulant, or blood thinner, used to lower the chance of stroke in patients with atrial fibrillation. It is also used to treat deep vein thrombosis in the legs and pulmonary embolisms in the lungs, particularly in patients who have had hip or knee replacement surgery. Coumadin (warfarin) is another medication used to treat and prevent clots in the veins.
Lot #HN0063, Eliquis 5mg tablets in 60-count bottles.
Expiration Date 09/2019. NDC 0003-0894-21
Tablets are distinguishable by color, shape and markings.
- 5mg tablets - pink, oval, biconvex, film-coated tablet with "894" debossed on one side and "5" on the other side.
- 2.5mg tablets - yellow, round, biconvex, film-coated tablet with “893” debossed on one side and “2½” on the other side
What to do if you have an affected product:
Patients concerned they have have been prescribed one of affected bottles are advised to contact Bristol-Myers Squibb's Customer Information Center on 1-800-332-2056 between 8am and 8pm EST Monday to Friday, or visit the company's website. They were also advised not to stop taking their medication without consulting with a physician. Missing doses or taking lower dosages could increase the risk of stroke, growing blood clots or moving blood clots, which potentially have life-threatening consequences.
Earlier this month, Phillips Company voluntarily recalled all lots of topical antibiotic products Tetrastem, Diabecline, Tetracycline-ABC, VenomX, Acneen, StaphWash, StringMed, NoPain and LidoMed. The announcement came following an FDA inspection found "significant manufacturing practices that calls into question the safety, identity, strength, quality and purity of unexpired drug products".
Anyone concerned with the quality of their medication or who experiences an adverse reaction to medicine should complete and submit a form online to the FDA MedWatch Adverse Event Reporting program.